Bank of America 13F: Adds $84M to ALNY Stake

Bank of America Increases Stake in Alnylam Pharmaceuticals

Bank of America has boosted its position in Alnylam Pharmaceuticals, Inc. (ALNY) by adding 281,735 shares, increasing its total holdings to 966,912 shares. This new stake is valued at approximately $288.2 million as of May 18, 2026, according to the latest Form 13F filing with the SEC.

What Changed in Bank of America's Position

This increase represents a 41.1% change in Bank of America's holdings. The fund's prior position was 685,177 shares, and this latest boost shows its ongoing confidence in Alnylam's prospects in the biotechnology sector.

Institutional Activity Around Alnylam

In the same quarter, other funds have also made notable changes to their positions in Alnylam Pharmaceuticals. For instance, Man Group increased its stake by 61.1%, reaching 232,369 shares valued at $66.8 million. Meanwhile, both Capital World Investors and Price T Rowe Associates trimmed their holdings by 33.7% and 15.9%, respectively, reflecting varied strategies among institutional investors.

How Alnylam Pharmaceuticals, Inc. Stock Has Traded

As of the publication date, Alnylam's stock was trading at $298.1, well above its 50-day moving average of $246.85. The stock has shown strong performance, with a 52-week range between $197.81 and $495.55. This increase in Bank of America's stake comes as the stock has been experiencing positive momentum.

Analysts Set New Price Targets

Analysts maintain a favorable outlook on Alnylam Pharmaceuticals. On October 14, 2026, Citigroup maintained a 'Buy' rating with a price target of $320.00, while Wells Fargo kept its 'Equal-Weight' rating with a target of $253.00. RBC Capital also maintained an 'Outperform' rating, setting a target of $345.00. The consensus rating remains a 'Buy', with a mean price target of $371.35 from 26 analysts.

What Alnylam Pharmaceuticals, Inc. Does

Alnylam Pharmaceuticals focuses on developing therapies based on ribonucleic acid interference. Its products address various serious health conditions, including hereditary amyloidosis and hypercholesterolemia. The company continues to advance its pipeline with several products in various phases of clinical trials, which is crucial for its growth.

What's Ahead for Alnylam Pharmaceuticals, Inc.

Investors will be watching Alnylam closely as it prepares to report its next earnings on October 29, 2026. The recent 13F filing reflects Bank of America's holdings as of May 18, 2026, and may not represent their current position. With ongoing developments in its clinical trials and product pipeline, Alnylam's future prospects remain of significant interest.